tetano
Editor, Senior Moderator
J Med Virol
. 2021 Jan 11.
doi: 10.1002/jmv.26789. Online ahead of print.
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome
Gabriele Anichini[SUP] 1 [/SUP], Claudia Gandolfo[SUP] 1 2 [/SUP], Chiara Terrosi[SUP] 1 [/SUP], Simonetta Fabrizi[SUP] 3 [/SUP], Giovanni Battista Miceli[SUP] 3 [/SUP], Gianni Gori Savellini[SUP] 1 [/SUP], Shibily Prathyumnan[SUP] 1 [/SUP], Federico Franchi[SUP] 4 [/SUP], Maria Grazia Cusi[SUP] 1 2 [/SUP]
Affiliations
Abstract
Data regarding antibody responses to SARS-CoV-2 in patients infected with COVID-19 are not yet available. In this study, we aimed to evaluate serum antibody responses in patients regardless of the outcome. We measured the circulating IgG antibody levels in 60 subjects with a certified history of SARS-CoV-2 infection by using immunoenzymatic, chemiluminescent, and Neutralization assays. Half patients had a severe infection, the other half were pauci-symptomatic. We analyzed their antibody response to see the trend of the humoral response. Our results showed a significant difference in circulating IgG level among the two groups. The neutralizing antibody response against SARS-CoV-2 was significantly higher among those who had severe disease. Furthermore, ten subjects from each group were screened twice, and a declining antibody trend was observed in pauci-symptomatic individuals. These findings provide evidence that humoral immunity against SARS-CoV-2 in pauci-symptomatic people is weak and may not be long-lasting. This may have implications for immunity strategy and prevention, since it is still not clear whether a time-dependent decrease of both circulating and neutralizing antibodies to non-protective levels could occur in a longer time span and whether potential vaccines are able to induce a herd immunity and a durable response. This article is protected by copyright. All rights reserved.
Keywords: Coronavirus; humoral immunity; neutralization.
. 2021 Jan 11.
doi: 10.1002/jmv.26789. Online ahead of print.
Antibody response to SARS-CoV-2 in infected patients with different clinical outcome
Gabriele Anichini[SUP] 1 [/SUP], Claudia Gandolfo[SUP] 1 2 [/SUP], Chiara Terrosi[SUP] 1 [/SUP], Simonetta Fabrizi[SUP] 3 [/SUP], Giovanni Battista Miceli[SUP] 3 [/SUP], Gianni Gori Savellini[SUP] 1 [/SUP], Shibily Prathyumnan[SUP] 1 [/SUP], Federico Franchi[SUP] 4 [/SUP], Maria Grazia Cusi[SUP] 1 2 [/SUP]
Affiliations
- PMID: 33427302
- DOI: 10.1002/jmv.26789
Abstract
Data regarding antibody responses to SARS-CoV-2 in patients infected with COVID-19 are not yet available. In this study, we aimed to evaluate serum antibody responses in patients regardless of the outcome. We measured the circulating IgG antibody levels in 60 subjects with a certified history of SARS-CoV-2 infection by using immunoenzymatic, chemiluminescent, and Neutralization assays. Half patients had a severe infection, the other half were pauci-symptomatic. We analyzed their antibody response to see the trend of the humoral response. Our results showed a significant difference in circulating IgG level among the two groups. The neutralizing antibody response against SARS-CoV-2 was significantly higher among those who had severe disease. Furthermore, ten subjects from each group were screened twice, and a declining antibody trend was observed in pauci-symptomatic individuals. These findings provide evidence that humoral immunity against SARS-CoV-2 in pauci-symptomatic people is weak and may not be long-lasting. This may have implications for immunity strategy and prevention, since it is still not clear whether a time-dependent decrease of both circulating and neutralizing antibodies to non-protective levels could occur in a longer time span and whether potential vaccines are able to induce a herd immunity and a durable response. This article is protected by copyright. All rights reserved.
Keywords: Coronavirus; humoral immunity; neutralization.